Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846403 | 0.91 | KDR (0.72) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL845964 | 0.91 | KDR (0.68) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL846074 | 0.90 | KDR (0.67) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL846379 | 0.90 | KDR (0.67) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL846300 | 0.90 | KDR (0.67) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL846030 | 0.90 | KDR (0.67) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL846520 | 0.88 | KDR (0.64) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL848116 | 0.88 | NPC1 (0.65) | NPC1KDM4EKDRRAB9AMITF | |
| SCHEMBL846927 | 0.88 | KDR (0.64) | NPC1KDM4ESMN1; SMN2HSD17B10KDR | |
| SCHEMBL846408 | 0.88 | KDR (0.64) | NPC1KDM4ESMN1; SMN2HSD17B10KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | claimed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | claimed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | claimed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | claimed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | NPC1 1518/4885KDM4E 3604/4885SMN1; SMN2 4426/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | NPC1 1518/4885KDM4E 3604/4885SMN1; SMN2 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.